Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14255720 | 0.92 | ADRB2 (0.49) | ADRB2CYP1A2CYP2D6TSHRNFKB1 | |
| SCHEMBL13181489 | 0.86 | ADRB2 (0.47) | ADRB2CYP1A2CYP2D6TSHRNFKB1 | |
| SCHEMBL12866429 | 0.84 | ADRB2 (0.46) | ADRB2CYP1A2CYP2D6TSHRNFKB1 | |
| SCHEMBL17635440 | 0.83 | ADRB2 (0.48) | ADRB2CYP1A2CYP2D6TSHRNFKB1 | |
| SCHEMBL10215349 | 0.83 | ADRB2 (0.54) | ADRB2CYP1A2CYP2D6TSHRNFKB1 | |
| SCHEMBL10450797 | 0.81 | ADRB2 (0.57) | ADRB2CYP1A2CYP2D6TSHRNFKB1 | |
| SCHEMBL22607306 | 0.81 | ADRB2 (0.57) | ADRB2CYP1A2CYP2D6TSHRNFKB1 | |
| SCHEMBL14622394 | 0.81 | ADRB2 (0.54) | ADRB2CYP1A2CYP2D6TSHRNFKB1 | |
| SCHEMBL14220262 | 0.81 | ADRB2 (0.57) | ADRB2CYP1A2CYP2D6TSHRNFKB1 | |
| SCHEMBL19983517 | 0.80 | ADRB2 (0.45) | ADRB2CYP1A2CYP2D6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2175863-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | Eastern Virginia Medical School (US) | 2010-04-21 | — | — | EP | claimed |
| WO-2009009625-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2009-01-15 | — | — | WO | claimed |
| US-20230173077-A1 | FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS | AJK Biopharmaceutical, LLC | 2023-06-08 | — | — | US | disclosed |
| WO-2021222807-A1 | FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS | AJK PHARMACEUTICAL LLC (US) | 2021-11-04 | — | — | WO | disclosed |
| US-9738678-B2 | Substituted nucleoside derivatives with antiviral and antimicrobial properties | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160311843-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2016-10-27 | — | — | US | disclosed |
| US-9296776-B2 | Substituted nucleoside derivatives with antiviral and antimicrobial properties | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2016-03-29 | — | — | US | disclosed |
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2175863-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | Eastern Virginia Medical School (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009009625-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009009625-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173077-A1 | FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS | ELOVL6, FADS2, FASN | ADRB2 3545/4885CYP1A2 148/4885CYP2D6 71/4885 |
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | SAMHD1, TLR3, MAVS | ADRB2 4016/4885CYP1A2 4420/4885CYP2D6 4405/4885 |
| US-20160311843-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | SAMHD1, TLR3, MAVS | ADRB2 4016/4885CYP1A2 4420/4885CYP2D6 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.